Ectopic Pregnancy. Ectopic pregnancy
Conditions
Interventions
Intervention 1: Intervention group: Methotrexate group: This group includes patients who receive methotrexate at a dose of 50 mg/m2 by intramuscular injection. The treatment is given once a day in one
Sponsors
Rasht University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: Diagnosis of ectopic pregnancy (confirmation of ectopic pregnancy diagnosis through ultrasound) Age between 18 and 45 years old The serum ß-hCG level is less than 5000 mIU/mL and the mass size is less than 4 cm. Have no history of chronic illness or other medical conditions (severe liver or kidney disease) Have no history of ectopic pregnancy treatment with other medications (such as methotrexate or letrozole) Willingness to participate in research Absence of acute symptoms, including heavy bleeding, acute abdominal pain, or signs of infection Patients must have confirmed ectopic pregnancy and be willing to undergo medical treatment.
Exclusion criteria
Exclusion criteria: The appearance of side effects (such as increased liver enzymes) The patient uses another treatment during the treatment process in this study Unwillingness to continue participating in the study If the patient is unable to participate in subsequent assessments for various reasons (such as not visiting the office for follow-up) Patients with unstable conditions and bleeding and emergencies Patients who have decided to undergo laparoscopic surgery
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Success in treatment. Timepoint: Measurement of beta-hCG titer on days 1-4-7 (decreased by 15% or more on day 7 compared to day 4). If there is a decrease of 15% or more, then once a week (days 14, 21, 28, etc.) and will continue until it reaches below 10. Method of measurement: Beta-hCG titer measurement.;Changes in ß-hCG levels. Timepoint: Days 1, 4, 7, 14, 21, 28, etc. (7-day intervals) after starting treatment. Method of measurement: Blood test. | — |
Secondary
| Measure | Time frame |
|---|---|
| Need for additional treatment. Timepoint: At the end of the first week and at the end of the second week after the start of treatment. Method of measurement: Recording information about patients who need additional doses or surgery.;The occurrence of treatment-related side effects such as nausea, vomiting, and liver damage, abdominal pain, diarrhea. Timepoint: Days 1, 4, 7, 14, 21, 28, etc. (7-day intervals) after starting treatment. Method of measurement: Visit and view patient records. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Seyedeh Hajar sharami
Rasht University of Medical Sciences
Outcome results
None listed